Uma Srivatsa, MD
Cardiovascular Disease · Sacramento, CANPI 1598747800
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 64.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $8,668 and has fallen 95.9% since, to $357 in 2025.
Across 80 payments — averaging $181.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Medtronic$3K
- Altathera Pharmaceuticals LLC$1K
- Boston Scientific$449
- Biosense Webster, Inc.$370
- Cardiva Medical, Inc.$171
- plus $129 from 4 others
Across 224 payments — averaging $219.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$49K
What the payments were for
- Consulting fees$7,15049%
- Speaking & faculty fees$1,0007%
- Travel & lodging$4,15929%
- Food & beverage$2,05714%
- Education$1301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $9,305 |
| Medtronic | 16 | $2,884 |
| Altathera Pharmaceuticals LLC | 2 | $1,188 |
| Boston Scientific | 11 | $449 |
| Biosense Webster, Inc. | 5 | $370 |
| Cardiva Medical, Inc. | 7 | $171 |
| Biotronik Inc. | 3 | $67 |
| Novartis | 1 | $25 |
| Convatec Inc. | 1 | $19 |
| Recor Medical Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$7,150
- AVEIR$1,761
- EVERA MRI XT DR SURESCAN$1,577
- Sotalol Hydrochloride$1,188
- EnSite Precision Cardiac Mapping System$157
- Carto 3$148
- Arctic Front$130
- RESONATE$117
How this compares
$14,496 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $169,536 |
| JardianceEmpagliflozin | 33 | $35,542 |
| XareltoRivaroxaban | 16 | $25,368 |
| EntrestoSacubitril/Valsartan | 26 | $18,812 |
| Amiodarone Hcl | 103 | $3,552 |
| Metoprolol Succinate | 107 | $1,969 |
| Flecainide Acetate | 38 | $1,280 |
| Verapamil ErVerapamil Hcl | 12 | $418 |
| Metoprolol Tartrate | 38 | $348 |
| Losartan Potassium | 22 | $296 |
| Atorvastatin Calcium | 34 | $174 |
| Amlodipine Besylate | 20 | $152 |
| Carvedilol | 15 | $128 |
| Furosemide | 22 | $55 |
| Lisinopril | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $25 | $18,81226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Sacramento
- Jason RogersSacramento$4.4M
- Gagan SinghSacramento$1.2M
- Thomas SmithSacramento$942K
- Edris AmanSacramento$516K
- Garrett WongSacramento$504K
- William BommerSacramento$194K
- Jeffrey SouthardSacramento$193K
- Andrea SoaresSacramento$159K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.